标题
Evaluation of the safety profile of COVID-19 vaccines: a rapid review
作者
关键词
-
出版物
BMC Medicine
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-28
DOI
10.1186/s12916-021-02059-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
- (2021) Tom Shimabukuro et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID‐19 vaccine — United States, December 21, 2020–January 10, 2021
- (2021) Tom Shimabukuro AMERICAN JOURNAL OF TRANSPLANTATION
- Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
- (2021) Tom T. Shimabukuro et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- (2021) Merryn Voysey et al. LANCET
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
- (2021) Peter Richmond et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
- (2021) Brian J. Boyarsky et al. TRANSPLANTATION
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
- (2021) Laurence Chu et al. VACCINE
- First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
- (2021) Julianne Gee et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration
- (2021) Kristine Vanijcharoenkarn et al. CLINICAL INFECTIOUS DISEASES
- Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation
- (2021) Dan Cohen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China
- (2021) Mei-Xian Zhang et al. Expert Review of Vaccines
- Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
- (2021) Johanna Chapin-Bardales et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
- (2021) Isaac See et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
- (2021) Cristina Menni et al. LANCET INFECTIOUS DISEASES
- Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
- (2021) Tom T. Shimabukuro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center
- (2021) William Daniel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
- (2021) Nina H. Schultz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atypical thrombosis associated with VaxZevria (AstraZeneca) vaccine: data from the French Network of Regional Pharmacovigilance Centres
- (2021) Valérie Gras-Champel et al. THERAPIE
- The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial
- (2021) Jing Pu et al. VACCINE
- Thrombosis after covid-19 vaccination
- (2021) Paul R Hunter BMJ-British Medical Journal
- Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
- (2021) Anton Pottegård et al. BMJ-British Medical Journal
- Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
- (2021) Guangfei Wang et al. Human Vaccines & Immunotherapeutics
- Association of Facial Paralysis With mRNA COVID-19 Vaccines
- (2021) Lucie Renoud et al. JAMA Internal Medicine
- Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
- (2021) David K. Shay et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
- (2021) Anne M. Hause et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?
- (2021) Giovanni de Simone et al. European Heart Journal-Cardiovascular Pharmacotherapy
- COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
- (2021) Zhi-Peng Yan et al. Pharmaceuticals
- Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19
- (2021) Behnood Bikdeli et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
- (2021) C. R. Simpson et al. NATURE MEDICINE
- Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents
- (2021) Barbara H. Bardenheier et al. VACCINE
- Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
- (2021) Michele Gringeri et al. Human Vaccines & Immunotherapeutics
- Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data
- (2021) Eric J. Formeister et al. JAMA Otolaryngology-Head & Neck Surgery
- COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says
- (2021) Gang Chen et al. Frontiers in Immunology
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
- (2021) John Frater et al. Lancet HIV
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
- (2020) Shengli Xia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing the Safety of COVID-19 Vaccines: A Primer
- (2020) Helen Petousis-Harris DRUG SAFETY
- Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US
- (2020) Grace M. Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- (2020) Jordan R. Barrett et al. NATURE MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Concerns and motivations about COVID-19 vaccination
- (2020) Rachael H Dodd et al. LANCET INFECTIOUS DISEASES
- Vaccine-associated hypersensitivity
- (2018) Michael M. McNeil et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The GRADE Working Group clarifies the construct of certainty of evidence
- (2017) Monica Hultcrantz et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now